Widely varying TNF-α levels in patients with myasthenia gravis

Neurological Sciences

Volumn 30, Issue 3, 2009, Pages 259-262

  Lee, Jin Soo ^a   Joo, In Soo ^a   Seok, Jung Im ^b  

^a Ajou University School of Medicine   (South Korea)

^b Catholic University of Daegu   (South Korea)

Author keywords

Acetylcholine receptor antibody; Myasthenia gravis; Quantitative myasthenia gravis score; Tumor necrosis factor alpha

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PYRIDOSTIGMINE; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; MYASTHENIA GRAVIS; PLASMAPHERESIS; PROTEIN BLOOD LEVEL; THYMECTOMY; THYMOMA;

ADULT; AGED; AUTOANTIBODIES; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, NICOTINIC; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67349158643     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-009-0023-0     Document Type: Article

References (12)

1. Drachman DC (1994) Myasthenia gravis. N Engl J Med 330:1797-1810
2. Christadoss P, Goluszko E (2002) Myasthenia gravis. In: Sarvetnick N, Hafler DA, Kuchroo VK (eds) Cytokines and autoimmune diseases. Hamana Press, Totowa, pp 373-385
3. Christadoss P, Goluszko E (2002) Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. J Neuroimmunol 122:186-190
4. Duan RS, Wang HB, Yang JS, Scallon B, Link H, Xiao BG (2002) Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis. J Autoimmun 19:169-174
5. Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G (1987) Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316:719-724
6. Lindstorm JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1976) Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates, and diagnostic value. Neurology 26:1054-1059
7. Zhang GX, Navikas V, Link H (1997) Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve 20:543-551
8. Ahlberg RE, Pirskanen R, Lefvert AK (1991) Defective T lymphocyte function in nonthymectomized patients with myasthenia gravis. Clin Immunol Immunopathol 60:93-105
9. Kakoulidou M, Bjelak S, Pirskanen R, Lefvert AK (2007) A clinical and immunological study of a myasthenia gravis patient treated with infliximab. Acta Neurol Scand 115:279-283
10. Rowin J, Meriggioli MN, Tuzun E, Leurgans S, Christadoss P (2004) Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 63:2390-2392
11. Tüzün E, Meriggioli MN, Rowin J, Yang H, Christadoss P (2005) Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J Autoimmun 24:261-268
12. Besinger UA, Toyka KV, Homberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A (1983) Myasthenia gravis: Long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33:1316-1321